tetano
Editor, Senior Moderator
NAR Genom Bioinform
. 2022 Aug 22;4(3):lqac058.
doi: 10.1093/nargab/lqac058. eCollection 2022 Sep.
A computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein S
Maryam Hajikarimlou[SUP] 1 [/SUP], Mohsen Hooshyar[SUP] 1 [/SUP], Mohamed Taha Moutaoufik[SUP] 2 [/SUP], Khaled A Aly[SUP] 2 [/SUP], Taha Azad[SUP] 3 [/SUP], Sarah Takallou[SUP] 1 [/SUP], Sasi Jagadeesan[SUP] 1 [/SUP], Sadhna Phanse[SUP] 2 [/SUP], Kamaledin B Said[SUP] 4 [/SUP], Bahram Samanfar[SUP] 1 [/SUP], John C Bell[SUP] 3 [/SUP], Frank Dehne[SUP] 5 [/SUP], Mohan Babu[SUP] 2 [/SUP], Ashkan Golshani[SUP] 1 [/SUP]
Affiliations
Abstract
The coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prompted the development of diagnostic and therapeutic frameworks for timely containment of this pandemic. Here, we utilized our non-conventional computational algorithm, InSiPS, to rapidly design and experimentally validate peptides that bind to SARS-CoV-2 spike (S) surface protein. We previously showed that this method can be used to develop peptides against yeast proteins, however, the applicability of this method to design peptides against other proteins has not been investigated. In the current study, we demonstrate that two sets of peptides developed using InSiPS method can detect purified SARS-CoV-2 S protein via ELISA and Surface Plasmon Resonance (SPR) approaches, suggesting the utility of our strategy in real time COVID-19 diagnostics. Mass spectrometry-based salivary peptidomics shortlist top SARS-CoV-2 peptides detected in COVID-19 patients' saliva, rendering them attractive SARS-CoV-2 diagnostic targets that, when subjected to our computational platform, can streamline the development of potent peptide diagnostics of SARS-CoV-2 variants of concern. Our approach can be rapidly implicated in diagnosing other communicable diseases of immediate threat.
. 2022 Aug 22;4(3):lqac058.
doi: 10.1093/nargab/lqac058. eCollection 2022 Sep.
A computational approach to rapidly design peptides that detect SARS-CoV-2 surface protein S
Maryam Hajikarimlou[SUP] 1 [/SUP], Mohsen Hooshyar[SUP] 1 [/SUP], Mohamed Taha Moutaoufik[SUP] 2 [/SUP], Khaled A Aly[SUP] 2 [/SUP], Taha Azad[SUP] 3 [/SUP], Sarah Takallou[SUP] 1 [/SUP], Sasi Jagadeesan[SUP] 1 [/SUP], Sadhna Phanse[SUP] 2 [/SUP], Kamaledin B Said[SUP] 4 [/SUP], Bahram Samanfar[SUP] 1 [/SUP], John C Bell[SUP] 3 [/SUP], Frank Dehne[SUP] 5 [/SUP], Mohan Babu[SUP] 2 [/SUP], Ashkan Golshani[SUP] 1 [/SUP]
Affiliations
- PMID: 36004308
- PMCID: PMC9394169
- DOI: 10.1093/nargab/lqac058
Abstract
The coronavirus disease 19 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prompted the development of diagnostic and therapeutic frameworks for timely containment of this pandemic. Here, we utilized our non-conventional computational algorithm, InSiPS, to rapidly design and experimentally validate peptides that bind to SARS-CoV-2 spike (S) surface protein. We previously showed that this method can be used to develop peptides against yeast proteins, however, the applicability of this method to design peptides against other proteins has not been investigated. In the current study, we demonstrate that two sets of peptides developed using InSiPS method can detect purified SARS-CoV-2 S protein via ELISA and Surface Plasmon Resonance (SPR) approaches, suggesting the utility of our strategy in real time COVID-19 diagnostics. Mass spectrometry-based salivary peptidomics shortlist top SARS-CoV-2 peptides detected in COVID-19 patients' saliva, rendering them attractive SARS-CoV-2 diagnostic targets that, when subjected to our computational platform, can streamline the development of potent peptide diagnostics of SARS-CoV-2 variants of concern. Our approach can be rapidly implicated in diagnosing other communicable diseases of immediate threat.